High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation

By C. Mu, Jian-an Huang, Ying Chen, Cheng Chen, Xue-guang Zhang. Medical Oncology, 2011

595 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

PD-L1 expression in human cancers and its association with clinical outcomes (2016, unknown): “Both the studies detected PD-L1 expression both on membrane and in cytoplasm of tumor cells, but the cut-off value for PD-L1 immunohistochemistry (IHC) positivity was not mentioned.(25,26) Azuma et al(26) revealed that expression of highaggregate PD-L1 on tumor cells is associated with EGFR gene mut”
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy (2015, background): “Tumor PD-L1 overexpression confers a poorer prognosis across multiple tumor histologies, making therapeutic intervention on this immunomodulatory axis enticing (19, 20, 21, 22).”
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. (2016, result): “1%) lung squamous cell carcinomas expressed membranous PD-L1, which is consistent with previous observations (Supplemental Figure 3B and D) (30-34).”